---
title: "Eliquis (apixaban) in nonvalvular atrial fibrillation: Dosing and administration questions"
description: "Dosing and administration questions on Eliquis (apixaban) in nonvalvular atrial fibrillation, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Taking treatment, Surgery and procedures, Dosing, and Switching anticoagulants. Questions: How long does Eliquis stay in your system (half-life)? What are the Eliquis precautions for spinal or epidural anesthesia? What is the Eliquis dosage for atrial fibrillation? When is the Eliquis dose reduced to 2.5 mg in atrial fibrillation? 9 further questions follow. 13 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/dosing-and-administration"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Eliquis (apixaban) in nonvalvular atrial fibrillation: Dosing and administration questions

Manufacturer: Bristol-Myers Squibb Company; Pfizer Inc  
Prescribing information: [Eliquis](https://packageinserts.bms.com/pi/pi_eliquis.pdf)

## Taking treatment

<a id="eliquis-half-life"></a>

### How long does Eliquis stay in your system (half-life)?

> “The half-life of ELIQUIS is approximately 12 hours following oral administration”

Source: [ELIQUIS: Dosing & Administration for NVAF, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/dosing/nvaf#:~:text=The%20half%2Dlife%20of%20ELIQUIS%20is%20approximately%2012%20hours%20following%20oral%20administration)

> “The pharmacodynamic effect of ELIQUIS can be expected to persist for at least 24 hours after the last dose, ie, for about two drug half lives”

Source: [ELIQUIS: Dosing & Administration for NVAF, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/dosing/nvaf#:~:text=The%20pharmacodynamic%20effect%20of%20ELIQUIS,about%20two%20drug%20half%20lives)

<a id="eliquis-missed-dose"></a>

### How is a missed Eliquis dose handled?

> “If a dose of ELIQUIS is not taken at the scheduled time, the dose should be taken as soon as possible on the same day and twice-daily administration should be resumed. The dose should not be doubled to make up for a missed dose.<sup>2</sup>”

Source: [ELIQUIS: Dosing & Administration for NVAF, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/dosing/nvaf#:~:text=If%20a%20dose%20of%20ELIQUIS,make%20up%20for%20a%20missed)

<a id="eliquis-crushing-tablets"></a>

### Can Eliquis tablets be crushed or given through a feeding tube?

> “For patients who are unable to swallow whole tablets, 5 mg and 2.5 mg ELIQUIS tablets may be crushed and suspended in water, 5% dextrose in water (D5W), or apple juice, or mixed with applesauce and promptly administered orally
> Alternatively, ELIQUIS tablets may be crushed and suspended in 60 mL of water or D5W and promptly delivered through a 12 French nasogastric tube. Following administration of the dose, the nasogastric tube should be flushed with an additional 20 mL of water or D5W.
> Crushed ELIQUIS tablets are stable in water, D5W, apple juice, and applesauce for up to 4 hours”

Source: [ELIQUIS: Dosing & Administration for NVAF, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/dosing/nvaf#:~:text=For%20patients%20who%20are%20unable,for%20up%20to%204%20hours)

<a id="eliquis-monitoring-food"></a>

### Does Eliquis require INR monitoring?

> “No international normalized ratio (INR) monitoring”

Source: [ELIQUIS: Dosing & Administration for NVAF, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/dosing/nvaf#:~:text=No%20international%20normalized%20ratio%20%28INR%29%20monitoring)

> “As a result of FXa inhibition, apixaban prolongs clotting tests such as prothrombin time (PT), 
> INR, and activated partial thromboplastin time (aPTT). Changes observed in these clotting tests 
> at the expected therapeutic dose, however, are small, subject to a high degree of variability, and 
> not useful in monitoring the anticoagulation effect of apixaban.”

Source: [ELIQUIS: Prescribing information, page 8, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=8)

<a id="eliquis-food"></a>

### Does Eliquis need to be taken with food?

> “No food restrictions or meal requirements”

Source: [ELIQUIS: Dosing & Administration for NVAF, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/dosing/nvaf#:~:text=No%20food%20restrictions%20or%20meal%20requirements)

> “Food does not affect the bioavailability of apixaban.”

Source: [ELIQUIS: Prescribing information, page 8, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=8)

## Surgery and procedures

<a id="eliquis-spinal-epidural"></a>

### What are the Eliquis precautions for spinal or epidural anesthesia?

> “Spinal/Epidural Anesthesia or Puncture: Patients treated with ELIQUIS undergoing spinal/epidural anesthesia or puncture may develop an epidural or spinal hematoma which can result in long-term or permanent paralysis. The risk of these events may be increased by the postoperative use of indwelling epidural catheters or the concomitant use of medicinal products affecting hemostasis. Indwelling epidural or intrathecal catheters should not be removed earlier than 24 hours after the last administration of ELIQUIS. The next dose of ELIQUIS should not be administered earlier than 5 hours after the removal of the catheter. The risk may also be increased by traumatic or repeated epidural or spinal puncture. If traumatic puncture occurs, delay the administration of ELIQUIS for 48 hours. Monitor patients frequently and if neurological compromise is noted, urgent diagnosis and treatment is necessary. Physicians should consider the potential benefit versus the risk of neuraxial intervention in ELIQUIS patients.”

Source: [ELIQUIS: NVAF Stroke Risk Efficacy & Safety Data, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/efficacy-safety/nvaf#:~:text=Spinal%2FEpidural%20Anesthesia%20or%20Puncture%3A%20Patients,neuraxial%20intervention%20in%20ELIQUIS%20patients.)

<a id="eliquis-surgery-interruption"></a>

### When should Eliquis be stopped before surgery?

> “ELIQUIS should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of unacceptable or clinically significant bleeding. ELIQUIS should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding or where the bleeding would be noncritical in location and easily controlled. Bridging anticoagulation during the 24 to 48 hours after stopping ELIQUIS and prior to the intervention is not generally required. ELIQUIS should be restarted after the surgical or other procedures as soon as adequate hemostasis has been established.”

Source: [ELIQUIS: Dosing & Administration for NVAF, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/dosing/nvaf#:~:text=ELIQUIS%20should%20be%20discontinued%20at,adequate%20hemostasis%20has%20been%20established.)

## Dosing

<a id="eliquis-nvaf-dose"></a>

### What is the Eliquis dosage for atrial fibrillation?

> “Recommended dose for most NVAF patients<sup>2</sup>:
>
> 5 mg twice daily
>
>
>
> In 2 phase III NVAF clinical trials, approximately 95% of ELIQUIS patients received this dose<sup>2-4</sup>”

Source: [ELIQUIS: Dosing & Administration for NVAF, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/dosing/nvaf#:~:text=Recommended%20dose%20for%20most%20NVAF,of%20ELIQUIS%20patients%20received%20this)

> “The recommended dose of ELIQUIS (apixaban) for most patients is 5 mg taken orally twice daily.”

Source: [ELIQUIS: Prescribing information, page 2, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=2)

<a id="eliquis-dose-reduction"></a>

### When is the Eliquis dose reduced to 2.5 mg in atrial fibrillation?

> “Dosage adjustment<sup>2</sup>:
>
> 2.5 mg twice daily
>
>
>
> Recommended dose for: Patients with at least 2 of the following
>
> age
> ≥80 years
>
> body weight
> ≤60 kg
>
> serum creatinine
> ≥1.5 mg/dL”

Source: [ELIQUIS: Dosing & Administration for NVAF, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/dosing/nvaf#:~:text=Dosage,%E2%89%A51.5%20mg%2FdL)

> “The recommended dose of ELIQUIS is 2.5 mg twice daily in patients with at least two of the 
> following characteristics:
> 	• age greater than or equal to 80 years
> 	• body weight less than or equal to 60 kg
> 	• serum creatinine greater than or equal to 1.5 mg/dL”

Source: [ELIQUIS: Prescribing information, page 2, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=2)

Note: The dosing page also calls for a 50% dose reduction in patients receiving 5 mg twice daily together with combined P-gp and strong CYP3A4 inhibitors.

<a id="eliquis-strengths"></a>

### What Eliquis tablet strengths are used for adults with atrial fibrillation?

> “ELIQUIS is available in 2.5 mg and 5 mg tablets.”

Source: [ELIQUIS: NVAF Stroke Risk Efficacy & Safety Data, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/efficacy-safety/nvaf#:~:text=ELIQUIS%20is%20available%20in%202.5%20mg%20and%205%20mg%20tablets.)

> “2.5 mg, yellow, round, biconvex, film-coated tablets with “893” debossed on one side 
> and “2½” on the other side.
> 	• 5 mg, pink, oval-shaped, biconvex, film-coated tablets with “894” debossed on one side 
> and “5” on the other side.”

Source: [ELIQUIS: Prescribing information, page 3, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=3)

## Switching anticoagulants

<a id="eliquis-switch-from-warfarin"></a>

### How do you switch from warfarin to Eliquis?

> “Warfarin to ELIQUIS	Discontinue warfarin and start ELIQUIS when international normalized ratio (INR) is <2.0.”

Source: [ELIQUIS: Dosing & Administration for NVAF, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/dosing/nvaf#:~:text=Warfarin%20to%20ELIQUIS,normalized%20ratio%20%28INR%29%20is%20%3C2.0.)

<a id="eliquis-switch-to-warfarin"></a>

### How do you switch from Eliquis to warfarin?

> “ELIQUIS to warfarin	ELIQUIS affects INR, so that initial INR measurements during transition to warfarin may not be useful for determining appropriate dose of warfarin. One approach is to discontinue ELIQUIS and begin both parenteral anticoagulant and warfarin at the time the next dose of ELIQUIS would have been taken, discontinuing the parenteral anticoagulant when INR reaches an acceptable range.”

Source: [ELIQUIS: Dosing & Administration for NVAF, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/dosing/nvaf#:~:text=ELIQUIS%20to%20warfarin,INR%20reaches%20an%20acceptable%20range.)

> “An increased rate of stroke was observed during the transition from ELIQUIS to warfarin in clinical trials in atrial fibrillation patients.”

Source: [ELIQUIS: NVAF Stroke Risk Efficacy & Safety Data, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/efficacy-safety/nvaf#:~:text=An%20increased%20rate%20of%20stroke,trials%20in%20atrial%20fibrillation%20patients.)

<a id="eliquis-switch-other-anticoagulants"></a>

### How do you switch between Eliquis and anticoagulants other than warfarin?

> “Anticoagulants other than warfarin (oral or parenteral) to ELIQUIS	Discontinue the anticoagulant other than warfarin and begin taking ELIQUIS at the usual time of the next dose of the anticoagulant other than warfarin.
> ELIQUIS to anticoagulants other than warfarin (oral or parenteral)	Discontinue ELIQUIS and begin taking the new anticoagulant other than warfarin at the usual time of the next dose of ELIQUIS.”

Source: [ELIQUIS: Dosing & Administration for NVAF, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/dosing/nvaf#:~:text=Anticoagulants%20other%20than%20warfarin%20%28oral,the%20next%20dose%20of%20ELIQUIS.)

## Related pages
- [Medical information: Eliquis (apixaban): Nonvalvular atrial fibrillation](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation)
- [Indication](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/safety)
- [Specific populations](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/drug-interactions)
- [Storage and supply](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/access-and-coverage)
